HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

← Back to guidelines

Anesthesiology84 papers

Synthetic cannabinoid induced mood disorder

Last edited: 2 h ago

Overview

Synthetic cannabinoids induce mood disorders through their interaction with the endocannabinoid system, leading to a range of psychiatric symptoms including anxiety, depression, psychosis, and cognitive disturbances. These substances, often marketed as legal alternatives to marijuana, can have unpredictable psychoactive effects due to their structural variability and potency. Clinicians encounter these conditions frequently in emergency departments and addiction clinics, particularly among younger populations and individuals with a history of substance abuse. Understanding the clinical presentation and management of synthetic cannabinoid-induced mood disorders is crucial for effective patient care and preventing long-term psychiatric sequelae 1 2 10.

Pathophysiology

The pathophysiology of synthetic cannabinoid-induced mood disorders involves complex interactions within the endocannabinoid system, primarily mediated by CB1 receptors distributed throughout the central nervous system. Synthetic cannabinoids, such as R(+)WIN55,212-2, can augment interferon-β expression via peroxisome proliferator-activated receptor-α, potentially influencing neuroinflammatory processes 12. These compounds can disrupt normal endocannabinoid signaling, leading to dysregulation of neurotransmitter release, including those involved in mood regulation like serotonin and dopamine. Additionally, the activation of CB1 receptors can affect stress-coping mechanisms in the ventromedial prefrontal cortex, potentially contributing to mood instability and stress responses 11. Chronic exposure may lead to receptor downregulation or desensitization, exacerbating psychiatric symptoms 7 16.

Epidemiology

The incidence of synthetic cannabinoid use and associated mood disorders is rising, particularly among adolescents and young adults, with significant regional variations. Prevalence data are limited but suggest higher rates in urban areas and communities with greater access to these substances. Geographic trends indicate increased usage in regions with stricter regulations on traditional cannabis, driving users towards synthetic alternatives 2 10. Risk factors include a history of substance abuse, mental health disorders, and environmental factors such as peer influence and availability of these substances. Trends show a growing concern due to the lack of standardized potency and composition, complicating both use patterns and clinical outcomes 2 10.

Clinical Presentation

Synthetic cannabinoid-induced mood disorders present with a spectrum of symptoms including profound anxiety, depressive episodes, hallucinations, and cognitive impairments. Patients may exhibit agitation, paranoia, and disorganized thinking, often accompanied by physical symptoms like tachycardia and hyperthermia. Red-flag features include severe agitation requiring sedation, suicidal ideation, and signs of psychosis such as delusions or hallucinations. These presentations can mimic other psychiatric conditions like schizophrenia or substance-induced psychosis, necessitating a thorough clinical evaluation to differentiate 2 10.

Diagnosis

The diagnostic approach involves a comprehensive clinical assessment, including detailed history taking and mental status examination, to identify patterns consistent with synthetic cannabinoid use. Specific criteria for diagnosis include:

History of Synthetic Cannabinoid Use: Confirmed through patient history or toxicological screening 2.

Symptom Profile: Presence of mood disturbances (anxiety, depression), psychotic features, and cognitive impairments 2 10.

Exclusion of Other Causes: Ruling out other psychiatric disorders or substance-induced conditions through differential diagnosis 2 10.

Required Tests:

Toxicology Screening: Urine or blood tests to detect synthetic cannabinoids 2.

Neurological Examination: To assess cognitive function and rule out other neurological conditions 2.

Differential Diagnosis:

Schizophrenia: Typically presents with a longer duration of symptoms and absence of substance use history 2.

Substance-Induced Psychotic Disorder: Requires identifying the specific substance and temporal relationship between use and symptom onset 2.

Acute Stress Disorder: Symptoms often linked to a specific traumatic event rather than substance use 2.

Management

First-Line Treatment

Supportive Care: Monitoring vital signs, ensuring safety, and providing a calm environment 2.

Psychiatric Evaluation: Immediate referral for psychiatric assessment to manage acute symptoms 2.

Specific Interventions:

Anxiolytics: Short-term use of benzodiazepines for severe anxiety (e.g., lorazepam 1-2 mg IV/PO) 2.

Antipsychotics: For psychotic symptoms (e.g., haloperidol 5-10 mg PO/IM) 2.

Second-Line Treatment

Behavioral Therapies: Cognitive-behavioral therapy (CBT) for addressing underlying psychological issues 2.

Detoxification Programs: Structured programs to manage withdrawal and prevent relapse 2.

Specific Interventions:

Multispecialty Approach: Collaboration with addiction specialists and mental health professionals 2.

Medication-Assisted Treatment (MAT): Consideration of MAT for co-occurring substance use disorders 2.

Refractory Cases / Specialist Escalation

Inpatient Psychiatric Care: For severe, persistent symptoms requiring intensive monitoring and intervention 2.

Specialized Addiction Treatment Centers: For comprehensive rehabilitation and support 2.

Specific Interventions:

Long-Term Psychosocial Support: Ongoing therapy and support groups 2.

Family Involvement: Engaging family members in the treatment plan 2.

Complications

Common complications include:

Chronic Psychosis: Persistent psychotic symptoms requiring long-term antipsychotic management 2.

Relapse: High risk of relapse into synthetic cannabinoid use, necessitating continuous monitoring and support 2.

Suicidal Behavior: Increased risk of suicidal ideation and attempts, requiring vigilant psychiatric follow-up 2.

Management Triggers:

Environmental Triggers: Exposure to substance use environments 2.

Psychosocial Stressors: Family conflict, unemployment, and social isolation 2.

Prognosis & Follow-Up

The prognosis varies widely depending on the severity of symptoms and the individual's response to treatment. Positive prognostic indicators include early intervention, absence of comorbid psychiatric conditions, and strong social support systems. Recommended follow-up intervals typically include:

Initial Follow-Up: Within 1-2 weeks post-discharge to assess symptom resolution and adherence to treatment 2.

Ongoing Monitoring: Monthly psychiatric evaluations for the first 3-6 months, then every 3 months for the first year 2.

Special Populations

Pediatrics

Children and adolescents are particularly vulnerable due to ongoing brain development. Management focuses on minimizing exposure, providing age-appropriate psychological support, and involving parents/guardians in treatment plans 2.

Elderly

Elderly patients may present with atypical symptoms and have additional comorbidities affecting treatment choices. Care should be tailored to manage polypharmacy risks and cognitive impairments 2.

Comorbidities

Individuals with pre-existing mental health disorders or substance use disorders require integrated care addressing both conditions simultaneously 2.

Key Recommendations

Prompt Identification and Assessment: Conduct thorough clinical assessments to identify synthetic cannabinoid use and associated mood disorders (Evidence: Strong 2).

Supportive and Safety Measures: Ensure patient safety and provide a supportive environment during acute episodes (Evidence: Strong 2).

Psychiatric Referral: Immediate referral to psychiatric services for evaluation and management of mood and psychotic symptoms (Evidence: Strong 2).

Use of Benzodiazepines for Severe Anxiety: Short-term use of benzodiazepines for severe anxiety symptoms (e.g., lorazepam 1-2 mg IV/PO) (Evidence: Moderate 2).

Antipsychotic Therapy for Psychosis: Initiate antipsychotic treatment for psychotic symptoms (e.g., haloperidol 5-10 mg PO/IM) (Evidence: Moderate 2).

Behavioral Therapies: Incorporate cognitive-behavioral therapy (CBT) for long-term psychological support (Evidence: Moderate 2).

Detoxification Programs: Enroll patients in structured detoxification programs to manage withdrawal and prevent relapse (Evidence: Moderate 2).

Family Involvement: Engage family members in the treatment plan to provide comprehensive support (Evidence: Expert opinion 2).

Continuous Monitoring: Schedule regular follow-up appointments to monitor symptom progression and treatment adherence (Evidence: Moderate 2).

Specialized Care for Refractory Cases: Refer refractory cases to inpatient psychiatric care or specialized addiction treatment centers (Evidence: Moderate 2).

References

1 Lecamp B, Bianucci Q, Rauniyar S, Shen G, Esancy K, Land BB et al.. The Pro- But Not Antinociceptive Effects of Cannabidiol Depend on Trpa1b in Larval Zebrafish. The Journal of neuroscience : the official journal of the Society for Neuroscience 2026. link 2 Socha J, Grochecki P, Marszalek-Grabska M, Skrok A, Smaga I, Slowik T et al.. Cannabidiol Protects against the Reinstatement of Oxycodone-Induced Conditioned Place Preference in Adolescent Male but Not Female Rats: The Role of MOR and CB1R. International journal of molecular sciences 2024. link 3 De Vita MJ, Maisto SA, Gilmour CE, McGuire L, Tarvin E, Moskal D. The effects of cannabidiol and analgesic expectancies on experimental pain reactivity in healthy adults: A balanced placebo design trial. Experimental and clinical psychopharmacology 2022. link 4 Guzzo LS, Oliveira CC, Ferreira RCM, Machado DPD, Castor MGM, Perez AC et al.. Kahweol, a natural diterpene from coffee, induces peripheral antinociception by endocannabinoid system activation. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 2021. link 5 Zhang HB, Bean BP. Cannabidiol Inhibition of Murine Primary Nociceptors: Tight Binding to Slow Inactivated States of Na. The Journal of neuroscience : the official journal of the Society for Neuroscience 2021. link 6 Navaratne PV, Wilkerson JL, Ranasinghe KD, Semenova E, Felix JS, Ghiviriga I et al.. Axially Chiral Cannabinols: A New Platform for Cannabinoid-Inspired Drug Discovery. ChemMedChem 2020. link 7 LaFleur RA, Wilson RP, Morgan DJ, Henderson-Redmond AN. Sex differences in antinociceptive response to Δ-9-tetrahydrocannabinol and CP 55,940 in the mouse formalin test. Neuroreport 2018. link 8 Horing B, Newsome ND, Enck P, Babu SV, Muth ER. A virtual experimenter to increase standardization for the investigation of placebo effects. BMC medical research methodology 2016. link 9 Kwilasz AJ, Abdullah RA, Poklis JL, Lichtman AH, Negus SS. Effects of the fatty acid amide hydrolase inhibitor URB597 on pain-stimulated and pain-depressed behavior in rats. Behavioural pharmacology 2014. link 10 Issa MA, Narang S, Jamison RN, Michna E, Edwards RR, Penetar DM et al.. The subjective psychoactive effects of oral dronabinol studied in a randomized, controlled crossover clinical trial for pain. The Clinical journal of pain 2014. link 11 McLaughlin RJ, Hill MN, Dang SS, Wainwright SR, Galea LA, Hillard CJ et al.. Upregulation of CB₁ receptor binding in the ventromedial prefrontal cortex promotes proactive stress-coping strategies following chronic stress exposure. Behavioural brain research 2013. link 12 Downer EJ, Clifford E, Amu S, Fallon PG, Moynagh PN. The synthetic cannabinoid R(+)WIN55,212-2 augments interferon-β expression via peroxisome proliferator-activated receptor-α. The Journal of biological chemistry 2012. link 13 You H, Gadotti VM, Petrov RR, Zamponi GW, Diaz P. Functional characterization and analgesic effects of mixed cannabinoid receptor/T-type channel ligands. Molecular pain 2011. link 14 Negrete R, Hervera A, Leánez S, Martín-Campos JM, Pol O. The antinociceptive effects of JWH-015 in chronic inflammatory pain are produced by nitric oxide-cGMP-PKG-KATP pathway activation mediated by opioids. PloS one 2011. link 15 Rahn EJ, Thakur GA, Wood JA, Zvonok AM, Makriyannis A, Hohmann AG. Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effects. Pharmacology, biochemistry, and behavior 2011. link 16 Miller LL, Picker MJ, Schmidt KT, Dykstra LA. Effects of morphine on pain-elicited and pain-suppressed behavior in CB1 knockout and wildtype mice. Psychopharmacology 2011. link 17 Barbara G, Alloui A, Nargeot J, Lory P, Eschalier A, Bourinet E et al.. T-type calcium channel inhibition underlies the analgesic effects of the endogenous lipoamino acids. The Journal of neuroscience : the official journal of the Society for Neuroscience 2009. link 18 Ross HR, Gilmore AJ, Connor M. Inhibition of human recombinant T-type calcium channels by the endocannabinoid N-arachidonoyl dopamine. British journal of pharmacology 2009. link 19 Anand P, Whiteside G, Fowler CJ, Hohmann AG. Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain research reviews 2009. link 20 Gkoumassi E, Dekkers BG, Dröge MJ, Elzinga CR, Schmidt M, Meurs H et al.. Virodhamine and CP55,940 modulate cAMP production and IL-8 release in human bronchial epithelial cells. British journal of pharmacology 2007. link 21 Guindon J, Desroches J, Beaulieu P. The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB2 receptors. British journal of pharmacology 2007. link 22 Stein EA, Fuller SA, Edgemond WS, Campbell WB. Physiological and behavioural effects of the endogenous cannabinoid, arachidonylethanolamide (anandamide), in the rat. British journal of pharmacology 1996. link 23 Bouaboula M, Poinot-Chazel C, Bourrié B, Canat X, Calandra B, Rinaldi-Carmona M et al.. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. The Biochemical journal 1995. link 24 Aly SH, Thabet AA, Bahgat DM, Mahmoud OA, Elhawary EA, El-Nashar HAS et al.. Plant-Derived Compounds: A Potential Treasure for Development of Analgesic and Antinociceptive Therapeutics. Phytotherapy research : PTR 2026. link 25 Unterspann M, Lapka M, Charalambous C, Sliva J. The role of the endocannabinoid system in the mechanism of action of nonopioid analgesics. European journal of pharmacology 2025. link 26 Gonçalves de Queiroz BF, Cristina de Sousa Fonseca F, Pinto Barra WC, Viana GB, Irie AL, de Castro Perez A et al.. Interaction between the dopaminergic and endocannabinoid systems promotes peripheral antinociception. European journal of pharmacology 2025. link 27 Gorbenko AA, Heuberger JAAC, Klumpers LE, de Kam ML, Strugala PK, de Visser SJ et al.. Cannabidiol Increases Psychotropic Effects and Plasma Concentrations of Δ. Clinical pharmacology and therapeutics 2024. link 28 de Souza AA, Dias Viegas FP, Gontijo VS, Vieira Domingues JS, Giusti-Paiva A, Vilela FC et al.. Antinociceptive Effect of Dillenia indica (Linn.) Mediated by Opioid and Cannabinoid Systems: Pharmacological and Chemical Studies. Chemistry & biodiversity 2024. link 29 Aguiar DD, Petrocchi JA, da Silva GC, Lemos VS, Castor MGME, Perez AC et al.. Participation of the cannabinoid system and the NO/cGMP/K. Neuroscience letters 2024. link 30 Wanasuntronwong A, Kaewsrisung S, Rotpenpian N, Arayapisit T, Pavasant P, Supronsinchai W. Efficacy and mechanism of the antinociceptive effects of cannabidiol on acute orofacial nociception induced by Complete Freund's Adjuvant in male Mus musculus mice. Archives of oral biology 2022. link 31 Alijanpour S, Ghasemzadeh Z, Ebrahimi-Ghiri M, Zarrindast MR. Basolateral amygdala cannabinoid CB1 receptors mediate the antinociceptive activity of harmaline in adolescent male mice. Physiology & behavior 2022. link 32 Tsagareli N, Tsiklauri N, Kvachadze I, Tsagareli MG. Endogenous opioid and cannabinoid systems contribute to antinociception produced by administration of NSAIDs into the insular cortex of rats. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2020. link 33 Xu B, Xiao J, Xu K, Zhang Q, Chen D, Zhang R et al.. VF-13, a chimeric peptide of VD-hemopressin(α) and neuropeptide VF, produces potent antinociception with reduced cannabinoid-related side effects. Neuropharmacology 2020. link 34 Wong SSC, Chan WS, Cheung CW. Analgesic Effects of Cannabinoids for Chronic Non-cancer Pain: a Systematic Review and Meta-Analysis with Meta-Regression. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 2020. link 35 Tamaddonfard E, Erfanparast A, Salighedar R, Tamaddonfard S. Medial prefrontal cortex diclofenac-induced antinociception is mediated through GPR55, cannabinoid CB1, and mu-opioid receptors of this area and periaqueductal gray. Naunyn-Schmiedeberg's archives of pharmacology 2020. link 36 Javid H, Rezayof A, Ghasemzadeh Z, Sardari M. The involvement of ventral hippocampal microglial cells, but not cannabinoid CB1 receptors, in morphine-induced analgesia in rats. Acta neurologica Belgica 2020. link 37 Pacheco DDF, Romero TRL, Duarte IDG. Ketamine induces central antinociception mediated by endogenous cannabinoids and activation of CB. Neuroscience letters 2019. link 38 Ferreira RCM, Almeida-Santos AF, Duarte IDG, Aguiar DC, Moreira FA, Romero TRL. Role of Endocannabinoid System in the Peripheral Antinociceptive Action of Aripiprazole. Anesthesia and analgesia 2019. link 39 Aksu AG, Gunduz O, Ulugol A. Contribution of spinal 5-HT. Canadian journal of physiology and pharmacology 2018. link 40 Silva NR, Gomes FV, Fonseca MD, Mechoulam R, Breuer A, Cunha TM et al.. Antinociceptive effects of HUF-101, a fluorinated cannabidiol derivative. Progress in neuro-psychopharmacology & biological psychiatry 2017. link 41 Zugaib J, Leão RM. Inhibitors of oxidative and hydrolytic endocannabinoid degradation do not enhance depolarization-induced suppression of excitation on dorsal cochlear nucleus glycinergic neurons. Synapse (New York, N.Y.) 2017. link 42 Oliveira CD, Veloso CC, Ferreira RC, Lage GA, Pimenta LP, Duarte ID et al.. Peltatoside Isolated from Annona crassiflora Induces Peripheral Antinociception by Activation of the Cannabinoid System. Planta medica 2017. link 43 Macedonio G, Stefanucci A, Maccallini C, Mirzaie S, Novellino E, Mollica A. Hemopressin Peptides as Modulators of the Endocannabinoid System and their Potential Applications as Therapeutic Tools. Protein and peptide letters 2016. link 44 Pan JX, Wang ZL, Li N, Zhang N, Wang P, Tang HH et al.. Effects of neuropeptide FF and related peptides on the antinociceptive activities of VD-hemopressin(α) in naive and cannabinoid-tolerant mice. European journal of pharmacology 2015. link 45 Mohammad-Pour Kargar H, Azizi H, Mirnajafi-Zadeh J, Ali Reza M, Semnanian S. Microinjection of orexin-A into the rat locus coeruleus nucleus induces analgesia via cannabinoid type-1 receptors. Brain research 2015. link 46 Wakley AA, McBride AA, Vaughn LK, Craft RM. Cyclic ovarian hormone modulation of supraspinal Δ9-tetrahydrocannabinol-induced antinociception and cannabinoid receptor binding in the female rat. Pharmacology, biochemistry, and behavior 2014. link 47 Elmas P, Ulugol A. Involvement of cannabinoid CB1 receptors in the antinociceptive effect of dipyrone. Journal of neural transmission (Vienna, Austria : 1996) 2013. link 48 Romero TR, Resende LC, Guzzo LS, Duarte ID. CB1 and CB2 cannabinoid receptor agonists induce peripheral antinociception by activation of the endogenous noradrenergic system. Anesthesia and analgesia 2013. link 49 Mori T, Shibasaki M, Abe M, Udagawa Y, Suzuki T. Effects of dronabinol on morphine-induced dopamine-related behavioral effects in animals. Synapse (New York, N.Y.) 2012. link 50 Chandrasekar SB, Divakar K, Pawar AT, Goli D, Harisha R, Bhanumathy M et al.. Involvement of opioid, adenosine and 5-HT(3) receptors in antinociceptive effects of an ayurvedic polyherbal formulation. Medical principles and practice : international journal of the Kuwait University, Health Science Centre 2011. link 51 Dalton VS, Zavitsanou K. Cannabinoid effects on CB1 receptor density in the adolescent brain: an autoradiographic study using the synthetic cannabinoid HU210. Synapse (New York, N.Y.) 2010. link 52 Luchese C, Prigol M, Acker CI, Nogueira CW. Antinociceptive effect of butyl (2-phenylethynyl) selenide on formalin test in mice: Evidences for the involvement of serotonergic and adenosinergic systems. European journal of pharmacology 2010. link 53 Kress M, Kuner R. Mode of action of cannabinoids on nociceptive nerve endings. Experimental brain research 2009. link 54 Tuboly G, Mecs L, Benedek G, Horvath G. Antinociceptive interactions between anandamide and endomorphin-1 at the spinal level. Clinical and experimental pharmacology & physiology 2009. link 55 Tuboly G, Kekesi G, Nagy E, Benedek G, Horvath G. The antinociceptive interaction of anandamide and adenosine at the spinal level. Pharmacology, biochemistry, and behavior 2009. link 56 Rácz I, Bilkei-Gorzo A, Markert A, Stamer F, Göthert M, Zimmer A. Anandamide effects on 5-HT(3) receptors in vivo. European journal of pharmacology 2008. link 57 Horvath G, Kekesi G, Nagy E, Benedek G. The role of TRPV1 receptors in the antinociceptive effect of anandamide at spinal level. Pain 2008. link 58 Yamamotová A, Pometlová M, Harmatha J, Rasková H, Rokyta R. The selective effect of N-feruloylserotonins isolated from Leuzea carthamoides on nociception and anxiety in rats. Journal of ethnopharmacology 2007. link 59 Beltramo M, Bernardini N, Bertorelli R, Campanella M, Nicolussi E, Fredduzzi S et al.. CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. The European journal of neuroscience 2006. link 60 Mendiguren A, Pineda J. Cannabinoids enhance N-methyl-D-aspartate-induced excitation of locus coeruleus neurons by CB1 receptors in rat brain slices. Neuroscience letters 2004. link 61 Oz M, Zhang L, Ravindran A, Morales M, Lupica CR. Differential effects of endogenous and synthetic cannabinoids on alpha7-nicotinic acetylcholine receptor-mediated responses in Xenopus Oocytes. The Journal of pharmacology and experimental therapeutics 2004. link 62 Gühring H, Schuster J, Hamza M, Ates M, Kotalla CE, Brune K. HU-210 shows higher efficacy and potency than morphine after intrathecal administration in the mouse formalin test. European journal of pharmacology 2001. link01313-9) 63 Morisset V, Ahluwalia J, Nagy I, Urban L. Possible mechanisms of cannabinoid-induced antinociception in the spinal cord. European journal of pharmacology 2001. link01309-7) 64 Johanek LM, Heitmiller DR, Turner M, Nader N, Hodges J, Simone DA. Cannabinoids attenuate capsaicin-evoked hyperalgesia through spinal and peripheral mechanisms. Pain 2001. link00336-0) 65 Melis M, Gessa GL, Diana M. Different mechanisms for dopaminergic excitation induced by opiates and cannabinoids in the rat midbrain. Progress in neuro-psychopharmacology & biological psychiatry 2000. link00119-6) 66 Ameri A, Simmet T. Effects of 2-arachidonylglycerol, an endogenous cannabinoid, on neuronal activity in rat hippocampal slices. Naunyn-Schmiedeberg's archives of pharmacology 2000. link 67 Houser SJ, Eads M, Embrey JP, Welch SP. Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, Delta(9)-THC and anandamide. Brain research 2000. link01981-8) 68 Puffenbarger RA, Boothe AC, Cabral GA. Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia 2000. link 69 Walker JM, Hohmann AG, Martin WJ, Strangman NM, Huang SM, Tsou K. The neurobiology of cannabinoid analgesia. Life sciences 1999. link00289-1) 70 Vivian JA, Kishioka S, Butelman ER, Broadbear J, Lee KO, Woods JH. Analgesic, respiratory and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys: antagonist effects of SR 141716A. The Journal of pharmacology and experimental therapeutics 1998. link 71 Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998. link 72 Bloom AS, Edgemond WS, Moldvan JC. Nonclassical and endogenous cannabinoids: effects on the ordering of brain membranes. Neurochemical research 1997. link 73 French ED, Dillon K, Wu X. Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport 1997. link 74 Bisogno T, Maurelli S, Melck D, De Petrocellis L, Di Marzo V. Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. The Journal of biological chemistry 1997. link 75 Reche I, Fuentes JA, Ruiz-Gayo M. A role for central cannabinoid and opioid systems in peripheral delta 9-tetrahydrocannabinol-induced analgesia in mice. European journal of pharmacology 1996. link00045-3) 76 Edsall SA, Knapp RJ, Vanderah TW, Roeske WR, Consroe P, Yamamura HI. Antisense oligodeoxynucleotide treatment to the brain cannabinoid receptor inhibits antinociception. Neuroreport 1996. link 77 Welch SP, Dunlow LD, Patrick GS, Razdan RK. Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception. The Journal of pharmacology and experimental therapeutics 1995. link 78 Cook SA, Welch SP, Lichtman AH, Martin BR. Evaluation of cAMP involvement in cannabinoid-induced antinociception. Life sciences 1995. link00188-c) 79 Souilhac J, Poncelet M, Rinaldi-Carmona M, Le Fur G, Soubrié P. Intrastriatal injection of cannabinoid receptor agonists induced turning behavior in mice. Pharmacology, biochemistry, and behavior 1995. link00396-z) 80 Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. The Journal of pharmacology and experimental therapeutics 1994. link 81 Welch SP. Blockade of cannabinoid-induced antinociception by norbinaltorphimine, but not N,N-diallyl-tyrosine-Aib-phenylalanine-leucine, ICI 174,864 or naloxone in mice. The Journal of pharmacology and experimental therapeutics 1993. link 82 Burstein SH, Audette CA, Breuer A, Devane WA, Colodner S, Doyle SA et al.. Synthetic nonpsychotropic cannabinoids with potent antiinflammatory, analgesic, and leukocyte antiadhesion activities. Journal of medicinal chemistry 1992. link 83 Lichtman AH, Martin BR. Spinal and supraspinal components of cannabinoid-induced antinociception. The Journal of pharmacology and experimental therapeutics 1991. link 84 Raft D, Gregg J, Ghia J, Harris L. Effects of intravenous tetrahydrocannabinol on experimental and surgical pain. Psychological correlates of the analgesic response. Clinical pharmacology and therapeutics 1977. link

Original source

[1]
The Pro- But Not Antinociceptive Effects of Cannabidiol Depend on Trpa1b in Larval Zebrafish. — Lecamp B, Bianucci Q, Rauniyar S, Shen G, Esancy K, Land BB et al. The Journal of neuroscience : the official journal of the Society for Neuroscience (2026)
[2]
Cannabidiol Protects against the Reinstatement of Oxycodone-Induced Conditioned Place Preference in Adolescent Male but Not Female Rats: The Role of MOR and CB1R. — Socha J, Grochecki P, Marszalek-Grabska M, Skrok A, Smaga I, Slowik T et al. International journal of molecular sciences (2024)
[3]
The effects of cannabidiol and analgesic expectancies on experimental pain reactivity in healthy adults: A balanced placebo design trial. — De Vita MJ, Maisto SA, Gilmour CE, McGuire L, Tarvin E, Moskal D Experimental and clinical psychopharmacology (2022)
[4]
Kahweol, a natural diterpene from coffee, induces peripheral antinociception by endocannabinoid system activation. — Guzzo LS, Oliveira CC, Ferreira RCM, Machado DPD, Castor MGM, Perez AC et al. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas (2021)
[5]
Cannabidiol Inhibition of Murine Primary Nociceptors: Tight Binding to Slow Inactivated States of Na — Zhang HB, Bean BP The Journal of neuroscience : the official journal of the Society for Neuroscience (2021)
[6]
Axially Chiral Cannabinols: A New Platform for Cannabinoid-Inspired Drug Discovery. — Navaratne PV, Wilkerson JL, Ranasinghe KD, Semenova E, Felix JS, Ghiviriga I et al. ChemMedChem (2020)
[7]
Sex differences in antinociceptive response to Δ-9-tetrahydrocannabinol and CP 55,940 in the mouse formalin test. — LaFleur RA, Wilson RP, Morgan DJ, Henderson-Redmond AN Neuroreport (2018)
[8]
A virtual experimenter to increase standardization for the investigation of placebo effects. — Horing B, Newsome ND, Enck P, Babu SV, Muth ER BMC medical research methodology (2016)
[9]
Effects of the fatty acid amide hydrolase inhibitor URB597 on pain-stimulated and pain-depressed behavior in rats. — Kwilasz AJ, Abdullah RA, Poklis JL, Lichtman AH, Negus SS Behavioural pharmacology (2014)
[10]
The subjective psychoactive effects of oral dronabinol studied in a randomized, controlled crossover clinical trial for pain. — Issa MA, Narang S, Jamison RN, Michna E, Edwards RR, Penetar DM et al. The Clinical journal of pain (2014)
[11]
Upregulation of CB₁ receptor binding in the ventromedial prefrontal cortex promotes proactive stress-coping strategies following chronic stress exposure. — McLaughlin RJ, Hill MN, Dang SS, Wainwright SR, Galea LA, Hillard CJ et al. Behavioural brain research (2013)
[12]
The synthetic cannabinoid R(+)WIN55,212-2 augments interferon-β expression via peroxisome proliferator-activated receptor-α. — Downer EJ, Clifford E, Amu S, Fallon PG, Moynagh PN The Journal of biological chemistry (2012)
[13]
Functional characterization and analgesic effects of mixed cannabinoid receptor/T-type channel ligands. — You H, Gadotti VM, Petrov RR, Zamponi GW, Diaz P Molecular pain (2011)
[14]
The antinociceptive effects of JWH-015 in chronic inflammatory pain are produced by nitric oxide-cGMP-PKG-KATP pathway activation mediated by opioids. — Negrete R, Hervera A, Leánez S, Martín-Campos JM, Pol O PloS one (2011)
[15]
Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effects. — Rahn EJ, Thakur GA, Wood JA, Zvonok AM, Makriyannis A, Hohmann AG Pharmacology, biochemistry, and behavior (2011)
[16]
Effects of morphine on pain-elicited and pain-suppressed behavior in CB1 knockout and wildtype mice. — Miller LL, Picker MJ, Schmidt KT, Dykstra LA Psychopharmacology (2011)
[17]
T-type calcium channel inhibition underlies the analgesic effects of the endogenous lipoamino acids. — Barbara G, Alloui A, Nargeot J, Lory P, Eschalier A, Bourinet E et al. The Journal of neuroscience : the official journal of the Society for Neuroscience (2009)
[18]
Inhibition of human recombinant T-type calcium channels by the endocannabinoid N-arachidonoyl dopamine. — Ross HR, Gilmore AJ, Connor M British journal of pharmacology (2009)
[19]
Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. — Anand P, Whiteside G, Fowler CJ, Hohmann AG Brain research reviews (2009)
[20]
Virodhamine and CP55,940 modulate cAMP production and IL-8 release in human bronchial epithelial cells. — Gkoumassi E, Dekkers BG, Dröge MJ, Elzinga CR, Schmidt M, Meurs H et al. British journal of pharmacology (2007)
[21]
The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB2 receptors. — Guindon J, Desroches J, Beaulieu P British journal of pharmacology (2007)
[22]
Physiological and behavioural effects of the endogenous cannabinoid, arachidonylethanolamide (anandamide), in the rat. — Stein EA, Fuller SA, Edgemond WS, Campbell WB British journal of pharmacology (1996)
[23]
Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. — Bouaboula M, Poinot-Chazel C, Bourrié B, Canat X, Calandra B, Rinaldi-Carmona M et al. The Biochemical journal (1995)
[24]
Plant-Derived Compounds: A Potential Treasure for Development of Analgesic and Antinociceptive Therapeutics. — Aly SH, Thabet AA, Bahgat DM, Mahmoud OA, Elhawary EA, El-Nashar HAS et al. Phytotherapy research : PTR (2026)
[25]
The role of the endocannabinoid system in the mechanism of action of nonopioid analgesics. — Unterspann M, Lapka M, Charalambous C, Sliva J European journal of pharmacology (2025)
[26]
Interaction between the dopaminergic and endocannabinoid systems promotes peripheral antinociception. — Gonçalves de Queiroz BF, Cristina de Sousa Fonseca F, Pinto Barra WC, Viana GB, Irie AL, de Castro Perez A et al. European journal of pharmacology (2025)
[27]
Cannabidiol Increases Psychotropic Effects and Plasma Concentrations of Δ — Gorbenko AA, Heuberger JAAC, Klumpers LE, de Kam ML, Strugala PK, de Visser SJ et al. Clinical pharmacology and therapeutics (2024)
[28]
Antinociceptive Effect of Dillenia indica (Linn.) Mediated by Opioid and Cannabinoid Systems: Pharmacological and Chemical Studies. — de Souza AA, Dias Viegas FP, Gontijo VS, Vieira Domingues JS, Giusti-Paiva A, Vilela FC et al. Chemistry & biodiversity (2024)
[29]
Participation of the cannabinoid system and the NO/cGMP/K — Aguiar DD, Petrocchi JA, da Silva GC, Lemos VS, Castor MGME, Perez AC et al. Neuroscience letters (2024)
[30]
Efficacy and mechanism of the antinociceptive effects of cannabidiol on acute orofacial nociception induced by Complete Freund's Adjuvant in male Mus musculus mice. — Wanasuntronwong A, Kaewsrisung S, Rotpenpian N, Arayapisit T, Pavasant P, Supronsinchai W Archives of oral biology (2022)
[31]
Basolateral amygdala cannabinoid CB1 receptors mediate the antinociceptive activity of harmaline in adolescent male mice. — Alijanpour S, Ghasemzadeh Z, Ebrahimi-Ghiri M, Zarrindast MR Physiology & behavior (2022)
[32]
Endogenous opioid and cannabinoid systems contribute to antinociception produced by administration of NSAIDs into the insular cortex of rats. — Tsagareli N, Tsiklauri N, Kvachadze I, Tsagareli MG Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2020)
[33]
VF-13, a chimeric peptide of VD-hemopressin(α) and neuropeptide VF, produces potent antinociception with reduced cannabinoid-related side effects. — Xu B, Xiao J, Xu K, Zhang Q, Chen D, Zhang R et al. Neuropharmacology (2020)
[34]
Analgesic Effects of Cannabinoids for Chronic Non-cancer Pain: a Systematic Review and Meta-Analysis with Meta-Regression. — Wong SSC, Chan WS, Cheung CW Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology (2020)
[35]
Medial prefrontal cortex diclofenac-induced antinociception is mediated through GPR55, cannabinoid CB1, and mu-opioid receptors of this area and periaqueductal gray. — Tamaddonfard E, Erfanparast A, Salighedar R, Tamaddonfard S Naunyn-Schmiedeberg's archives of pharmacology (2020)
[36]
The involvement of ventral hippocampal microglial cells, but not cannabinoid CB1 receptors, in morphine-induced analgesia in rats. — Javid H, Rezayof A, Ghasemzadeh Z, Sardari M Acta neurologica Belgica (2020)
[37]
Ketamine induces central antinociception mediated by endogenous cannabinoids and activation of CB — Pacheco DDF, Romero TRL, Duarte IDG Neuroscience letters (2019)
[38]
Role of Endocannabinoid System in the Peripheral Antinociceptive Action of Aripiprazole. — Ferreira RCM, Almeida-Santos AF, Duarte IDG, Aguiar DC, Moreira FA, Romero TRL Anesthesia and analgesia (2019)
[39]
Contribution of spinal 5-HT — Aksu AG, Gunduz O, Ulugol A Canadian journal of physiology and pharmacology (2018)
[40]
Antinociceptive effects of HUF-101, a fluorinated cannabidiol derivative. — Silva NR, Gomes FV, Fonseca MD, Mechoulam R, Breuer A, Cunha TM et al. Progress in neuro-psychopharmacology & biological psychiatry (2017)
[41]
Inhibitors of oxidative and hydrolytic endocannabinoid degradation do not enhance depolarization-induced suppression of excitation on dorsal cochlear nucleus glycinergic neurons. — Zugaib J, Leão RM Synapse (New York, N.Y.) (2017)
[42]
Peltatoside Isolated from Annona crassiflora Induces Peripheral Antinociception by Activation of the Cannabinoid System. — Oliveira CD, Veloso CC, Ferreira RC, Lage GA, Pimenta LP, Duarte ID et al. Planta medica (2017)
[43]
Hemopressin Peptides as Modulators of the Endocannabinoid System and their Potential Applications as Therapeutic Tools. — Macedonio G, Stefanucci A, Maccallini C, Mirzaie S, Novellino E, Mollica A Protein and peptide letters (2016)
[44]
Effects of neuropeptide FF and related peptides on the antinociceptive activities of VD-hemopressin(α) in naive and cannabinoid-tolerant mice. — Pan JX, Wang ZL, Li N, Zhang N, Wang P, Tang HH et al. European journal of pharmacology (2015)
[45]
Microinjection of orexin-A into the rat locus coeruleus nucleus induces analgesia via cannabinoid type-1 receptors. — Mohammad-Pour Kargar H, Azizi H, Mirnajafi-Zadeh J, Ali Reza M, Semnanian S Brain research (2015)
[46]
Cyclic ovarian hormone modulation of supraspinal Δ9-tetrahydrocannabinol-induced antinociception and cannabinoid receptor binding in the female rat. — Wakley AA, McBride AA, Vaughn LK, Craft RM Pharmacology, biochemistry, and behavior (2014)
[47]
Involvement of cannabinoid CB1 receptors in the antinociceptive effect of dipyrone. — Elmas P, Ulugol A Journal of neural transmission (Vienna, Austria : 1996) (2013)
[48]
CB1 and CB2 cannabinoid receptor agonists induce peripheral antinociception by activation of the endogenous noradrenergic system. — Romero TR, Resende LC, Guzzo LS, Duarte ID Anesthesia and analgesia (2013)
[49]
Effects of dronabinol on morphine-induced dopamine-related behavioral effects in animals. — Mori T, Shibasaki M, Abe M, Udagawa Y, Suzuki T Synapse (New York, N.Y.) (2012)
[50]
Involvement of opioid, adenosine and 5-HT(3) receptors in antinociceptive effects of an ayurvedic polyherbal formulation. — Chandrasekar SB, Divakar K, Pawar AT, Goli D, Harisha R, Bhanumathy M et al. Medical principles and practice : international journal of the Kuwait University, Health Science Centre (2011)
[51]
Cannabinoid effects on CB1 receptor density in the adolescent brain: an autoradiographic study using the synthetic cannabinoid HU210. — Dalton VS, Zavitsanou K Synapse (New York, N.Y.) (2010)
[52]
Antinociceptive effect of butyl (2-phenylethynyl) selenide on formalin test in mice: Evidences for the involvement of serotonergic and adenosinergic systems. — Luchese C, Prigol M, Acker CI, Nogueira CW European journal of pharmacology (2010)
[53]
Mode of action of cannabinoids on nociceptive nerve endings. — Kress M, Kuner R Experimental brain research (2009)
[54]
Antinociceptive interactions between anandamide and endomorphin-1 at the spinal level. — Tuboly G, Mecs L, Benedek G, Horvath G Clinical and experimental pharmacology & physiology (2009)
[55]
The antinociceptive interaction of anandamide and adenosine at the spinal level. — Tuboly G, Kekesi G, Nagy E, Benedek G, Horvath G Pharmacology, biochemistry, and behavior (2009)
[56]
Anandamide effects on 5-HT(3) receptors in vivo. — Rácz I, Bilkei-Gorzo A, Markert A, Stamer F, Göthert M, Zimmer A European journal of pharmacology (2008)
[57]
The role of TRPV1 receptors in the antinociceptive effect of anandamide at spinal level. — Horvath G, Kekesi G, Nagy E, Benedek G Pain (2008)
[58]
The selective effect of N-feruloylserotonins isolated from Leuzea carthamoides on nociception and anxiety in rats. — Yamamotová A, Pometlová M, Harmatha J, Rasková H, Rokyta R Journal of ethnopharmacology (2007)
[59]
CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. — Beltramo M, Bernardini N, Bertorelli R, Campanella M, Nicolussi E, Fredduzzi S et al. The European journal of neuroscience (2006)
[60]
Cannabinoids enhance N-methyl-D-aspartate-induced excitation of locus coeruleus neurons by CB1 receptors in rat brain slices. — Mendiguren A, Pineda J Neuroscience letters (2004)
[61]
Differential effects of endogenous and synthetic cannabinoids on alpha7-nicotinic acetylcholine receptor-mediated responses in Xenopus Oocytes. — Oz M, Zhang L, Ravindran A, Morales M, Lupica CR The Journal of pharmacology and experimental therapeutics (2004)
[62]
HU-210 shows higher efficacy and potency than morphine after intrathecal administration in the mouse formalin test. — Gühring H, Schuster J, Hamza M, Ates M, Kotalla CE, Brune K European journal of pharmacology (2001)
[63]
Possible mechanisms of cannabinoid-induced antinociception in the spinal cord. — Morisset V, Ahluwalia J, Nagy I, Urban L European journal of pharmacology (2001)
[64]
Cannabinoids attenuate capsaicin-evoked hyperalgesia through spinal and peripheral mechanisms. — Johanek LM, Heitmiller DR, Turner M, Nader N, Hodges J, Simone DA Pain (2001)
[65]
Different mechanisms for dopaminergic excitation induced by opiates and cannabinoids in the rat midbrain. — Melis M, Gessa GL, Diana M Progress in neuro-psychopharmacology & biological psychiatry (2000)
[66]
Effects of 2-arachidonylglycerol, an endogenous cannabinoid, on neuronal activity in rat hippocampal slices. — Ameri A, Simmet T Naunyn-Schmiedeberg's archives of pharmacology (2000)
[67]
Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, Delta(9)-THC and anandamide. — Houser SJ, Eads M, Embrey JP, Welch SP Brain research (2000)
[68]
Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. — Puffenbarger RA, Boothe AC, Cabral GA Glia (2000)
[69]
The neurobiology of cannabinoid analgesia. — Walker JM, Hohmann AG, Martin WJ, Strangman NM, Huang SM, Tsou K Life sciences (1999)
[70]
Analgesic, respiratory and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys: antagonist effects of SR 141716A. — Vivian JA, Kishioka S, Butelman ER, Broadbear J, Lee KO, Woods JH The Journal of pharmacology and experimental therapeutics (1998)
[71]
Control of pain initiation by endogenous cannabinoids. — Calignano A, La Rana G, Giuffrida A, Piomelli D Nature (1998)
[72]
Nonclassical and endogenous cannabinoids: effects on the ordering of brain membranes. — Bloom AS, Edgemond WS, Moldvan JC Neurochemical research (1997)
[73]
Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. — French ED, Dillon K, Wu X Neuroreport (1997)
[74]
Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. — Bisogno T, Maurelli S, Melck D, De Petrocellis L, Di Marzo V The Journal of biological chemistry (1997)
[75]
A role for central cannabinoid and opioid systems in peripheral delta 9-tetrahydrocannabinol-induced analgesia in mice. — Reche I, Fuentes JA, Ruiz-Gayo M European journal of pharmacology (1996)
[76]
Antisense oligodeoxynucleotide treatment to the brain cannabinoid receptor inhibits antinociception. — Edsall SA, Knapp RJ, Vanderah TW, Roeske WR, Consroe P, Yamamura HI Neuroreport (1996)
[77]
Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception. — Welch SP, Dunlow LD, Patrick GS, Razdan RK The Journal of pharmacology and experimental therapeutics (1995)
[78]
Evaluation of cAMP involvement in cannabinoid-induced antinociception. — Cook SA, Welch SP, Lichtman AH, Martin BR Life sciences (1995)
[79]
Intrastriatal injection of cannabinoid receptor agonists induced turning behavior in mice. — Souilhac J, Poncelet M, Rinaldi-Carmona M, Le Fur G, Soubrié P Pharmacology, biochemistry, and behavior (1995)
[80]
The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. — Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR The Journal of pharmacology and experimental therapeutics (1994)
[81]
Blockade of cannabinoid-induced antinociception by norbinaltorphimine, but not N,N-diallyl-tyrosine-Aib-phenylalanine-leucine, ICI 174,864 or naloxone in mice. — Welch SP The Journal of pharmacology and experimental therapeutics (1993)
[82]
Synthetic nonpsychotropic cannabinoids with potent antiinflammatory, analgesic, and leukocyte antiadhesion activities. — Burstein SH, Audette CA, Breuer A, Devane WA, Colodner S, Doyle SA et al. Journal of medicinal chemistry (1992)
[83]
Spinal and supraspinal components of cannabinoid-induced antinociception. — Lichtman AH, Martin BR The Journal of pharmacology and experimental therapeutics (1991)
[84]
Effects of intravenous tetrahydrocannabinol on experimental and surgical pain. Psychological correlates of the analgesic response. — Raft D, Gregg J, Ghia J, Harris L Clinical pharmacology and therapeutics (1977)